/NVST
NVST Stock - Envista Holdings Corp
Healthcare|Medical - Equipment & ServicesNYSE
$22.28+0.13%
+$0.03 (+0.13%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).65
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+7.7%upside
Target: $24.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$22.06 – $22.50
TARGET (TP)$24.00
STOP LOSS$20.50
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.03
52W High$22.68
52W Low$14.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.51B | $2.57B | $2.57B | $2.51B | $1.93B |
| Gross Profit | $1.39B | $1.45B | $1.49B | $1.46B | $1.07B |
| Gross Margin | 55.4% | 56.5% | 57.9% | 58.3% | 55.6% |
| Operating Income | $-1,038,200,000 | $31.50M | $319.20M | $306.20M | $43.50M |
| Net Income | $-1,118,600,000 | $-100,200,000 | $243.10M | $340.50M | $33.30M |
| Net Margin | -44.6% | -3.9% | 9.5% | 13.6% | 1.7% |
| EPS | $-6.50 | $-0.60 | $1.46 | $1.63 | $0.27 |
Company Overview
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
8%
Hold / Neutral
8
67%
Sell / Underperform
3
25%
Analyst Consensus🔴 Bearish
1 Bullish11 Neutral/Bearish
Price Targets
$25
Average Target
↑ 13.5% Upside
Now
$16
Low
$25
Average
$46
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $24 |
| May 27th 2025 | Robert W. Baird | Upgrade | Outperform | $23 |
| December 4th 2024 | Mizuho | Initiation | Underperform | $20 |
| October 31st 2024 | Leerink Partners | Upgrade | Market Perform | $23← $16 |
| October 8th 2024 | Wells Fargo | Initiation | Equal Weight | $20 |
| August 8th 2024 | JP Morgan | Downgrade | Neutral | $16← $23 |
| April 26th 2024 | Morgan Stanley | Downgrade | Equal Weight | $21← $33 |
| February 26th 2024 | Leerink Partners | Initiation | Underperform | $19 |
| February 9th 2024 | Jefferies | Downgrade | Hold | $23← $30 |
| February 8th 2024 | William Blair | Downgrade | Market Perform | - |
| January 5th 2024 | UBS | Initiation | Neutral | $26 |
| December 11th 2023 | Goldman | Downgrade | Sell | $22 |
| November 16th 2023 | Needham | Initiation | Hold | - |
| November 2nd 2023 | Piper Sandler | Downgrade | Neutral | $25← $39 |
| August 29th 2022 | Piper Sandler | Upgrade | Overweight | $46← $40 |
Earnings History & Surprises
NVSTBeat Rate
67%
Last 18 quarters
Avg Surprise
+2.5%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$0.32
Q4 2025
EPS Surprise History
Q1 24
-12.1%
$0.29vs$0.33
Q2 24
-16.1%
$0.26vs$0.31
Q3 24
-59.3%
$0.11vs$0.27
Q4 24
+33.3%
$0.12vs$0.09
Q1 25
+4.3%
$0.24vs$0.23
Q2 25
+20.0%
$0.24vs$0.20
Q3 25
+8.3%
$0.26vs$0.24
Q4 25
+18.5%
$0.32vs$0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.32 | — | — | — |
Q4 2025 | Oct 29, 2025 | $0.27 | $0.32 | +18.5% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.24 | $0.26 | +8.3% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.20 | $0.24 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $0.23 | $0.24 | +4.3% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.09 | $0.12 | +33.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.27 | $0.11 | -59.3% | ✗ MISS |
Q2 2024 | May 1, 2024 | $0.31 | $0.26 | -16.1% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $0.33 | $0.29 | -12.1% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $0.46 | $0.43 | -6.5% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $0.41 | $0.43 | +4.9% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.41 | $0.38 | -7.3% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $0.49 | $0.52 | +6.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.47 | $0.47 | 0.0% | = MET |
Q3 2022 | Aug 3, 2022 | $0.46 | $0.48 | +4.3% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $0.43 | $0.47 | +9.3% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $0.42 | $0.46 | +9.5% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.41 | $0.45 | +9.8% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.45 | $0.53 | +17.8% | ✓ BEAT |
Latest News
JP Morgan Maintains Neutral on Envista Holdings, Raises Price Target to $22
➖ NeutralBenzinga•Dec 16, 2025, 03:41 PM
NVST stock has given up its prior gain. Envista Holdings shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 adjusted EPS guidance.
➖ NeutralBenzinga•Oct 30, 2025, 05:22 PM
Envista Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 adjusted EPS guidance.
📈 PositiveBenzinga•Oct 30, 2025, 12:51 PM
Envista Raises FY 2025 Adjusted Diluted EPS Outlook To $1.10–$1.15, Up From Prior Range Of $1.05–$1.15
📈 PositiveBenzinga•Oct 30, 2025, 07:42 AM
Envista Holdings Q3 Adj. EPS $0.32 Beats $0.28 Estimate, Sales $669.900M Beat $640.915M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 07:36 AM
Frequently Asked Questions about NVST
What is NVST's current stock price?
Envista Holdings Corp (NVST) is currently trading at $22.28 per share. The stock has moved +0.13% today.
What is the analyst price target for NVST?
The average analyst price target for NVST is $24.00, based on 1 analyst.
What sector is Envista Holdings Corp in?
Envista Holdings Corp operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. The company is traded on the NYSE exchange.
What is NVST's market cap?
Envista Holdings Corp has a market capitalization of $3.66 billion, making it a mid-cap company.
Does NVST pay dividends?
No, Envista Holdings Corp does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALHC
Alignment Healthcare, Inc.
$20.42
Mkt Cap: $4.1B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CON
Concentra Group Holdings Parent, Inc.
$19.43
Mkt Cap: $2.5B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
GRAL
GRAIL, Inc.
$91.09
Mkt Cap: $3.2B
ICUI
ICU Medical, Inc.
$145.15
Mkt Cap: $3.6B
PRVA
Privia Health Group, Inc.
$23.64
Mkt Cap: $2.9B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SUPN
Supernus Pharmaceuticals, Inc.
$51.48
Mkt Cap: $2.9B
XRAY
DENTSPLY SIRONA Inc.
$11.21
Mkt Cap: $2.2B
Explore stocks similar to NVST for comparison